Skip to main content
Advertisement
  • Loading metrics

Correction: Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India

  • V. Ramesh,
  • Ruchi Singh,
  • Kumar Avishek,
  • Aditya Verma,
  • Deepak Kumar Deep,
  • Sandeep Verma,
  • Poonam Salotra
  • Article
  • Metrics
  • Comments
  • Media Coverage

Fig 3 and Fig 4 are incorrect. The authors have provided corrected versions here.

thumbnail
Fig 3. Scatter plot showing parasite load at the pre-treatment stage in the cases that eventually relapsed vs those that remained cured.

Parasite load was determined by Q-PCR in slit aspirate sample at the time of diagnosis of PKDL and expressed as the number of Leishmania parasite/μl slit aspirate. P value was calculated using Mann-Whitney test. Horizontal bars indicate mean± SEM.

https://doi.org/10.1371/journal.pntd.0004289.g001

thumbnail
Fig 4. In vitro MIL susceptibility of parasite isolates from cured (n = 7) and relapsed (n = 6) PKDL patients.

MIL susceptibility at (A) promastigote stage (B) amastigote stage. Each individual value represents mean IC50± SD of the results from two separate assays. P value was calculated using Mann-Whitney test. Horizontal bars indicate mean ±SEM

https://doi.org/10.1371/journal.pntd.0004289.g002

Reference

  1. 1. Ramesh V, Singh R, Avishek K, Verma A, Deep DK, Verma S, et al. (2015) Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India. PLoS Negl Trop Dis 9(10): e0004093. pmid:26492039